ABL1 and acute lymphoblastic leukemia: It is for the first time that our study applied a molecular strategy to explore the periodic assessments of BCR-ABL1 transcripts in patients with Ph+ B-ALL post-CD19/22 CAR-T therapy using ddPCR.